Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dynavax

11.43
-0.0150-0.13%
Volume:153.99K
Turnover:1.76M
Market Cap:1.42B
PE:57.13
High:11.46
Open:11.38
Low:11.36
Close:11.44
Loading ...

Company Profile

Company Name:
Dynavax
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
405
Office Location:
2100 Powell Street,Suite 720,EmeryVille,California,United States
Zip Code:
94608
Fax:
510 848 1327
Introduction:
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Directors

Name
Position
Eddie Gray
Chief Executive Officer and Director
Arnold L. Oronsky
Chairperson of the Board
Daniel L. Kisner
Director
Dennis Carson
Director
Francis R. Cano
Director
Laura Brege
Director
Natale Ricciardi
Director
Peggy V. Phillips
Director
Stanley A. Plotkin
Director

Shareholders

Name
Position
Eddie Gray
Chief Executive Officer and Director
David F. Novak
Senior Vice President, Operations and Quality
Michael S. Ostrach
Senior Vice President, Chief Financial Officer and Chief Business Officer
Robert L. Coffman
Senior Vice President and Chief Scientific Officer
Robert Janssen
Chief Medical Officer and Vice President, Clinical Development